Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
26.40    -0.10 (-0.38%)
Bid:
26.50
Ask:
26.90
Spread: 0.40 (1.509%)
Market Cap: £113.65m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Extension to deadline under Rule 2.6(c)

19 Oct 2015 07:00

RNS Number : 6078C
EKF Diagnostics Holdings PLC
19 October 2015
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

 

This is an announcement falling under Rule 2.4 of the Takeover Code and does not constitute an announcement of a firm intention to make an offer under Rule 2.7 of the Takeover Code. There can be no certainty that an offer will be made nor as to the terms on which any offer might be made.

 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Extension to deadline under Rule 2.6(c) of the City Code on Takeovers and Mergers (the "Code")

 

On 24 August 2015 the board of EKF (the "Board") announced that it had received a proposal from Jinjing (Group) Co., Ltd ("Jinjing") regarding a possible offer for the whole of the issued and to be issued ordinary share capital of the Company.

 

The original deadline for Jinjing to either announce a firm intention to make an offer for the Company or announce that it does not intend to make an offer was 5 p.m. on 18 September 2015. This deadline was subsequently extended, with the consent of the Panel on Takeovers and Mergers (the "Panel"), to 5 p.m. on 19 October 2015.

 

The parties are working together to conclude confirmatory due diligence and to agree the terms of a possible transaction, which includes, amongst other things, continuing discussions on the offer structure. Alternative structures under consideration include a cash offer by Jinjing for the entire issued share capital of EKF in combination with a distribution by EKF of its interests in its Molecular business to existing shareholders or a sale of certain assets by EKF to Jinjing in combination with a return of value by EKF to existing shareholders.

 

In accordance with Rule 2.6(c) of the Code, the Board has requested that the Panel extend the relevant deadline, as referred to above, to enable the parties to continue their discussions regarding a possible offer. Accordingly, an extension has been granted by the Panel and Jinjing must, by no later than 5 p.m. on 23 October 2015, either announce a firm intention to make an offer for EKF in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline will only be extended with the consent of the Panel.

 

A further announcement will be made when appropriate. In the meantime, EKF shareholders are advised by the Board to take no action. There can be no certainty that any formal offer for the Company will be forthcoming, nor as to the terms of any such formal offer.

 

This announcement has been made with the agreement and approval of Jinjing.

 

Enquiries:

EKF Diagnostics Holdings plc

Tel: 029 2071 0570

David Evans, Executive Chairman

Mob: 07740 084 452

Julian Baines, CEO

Mob: 07788 420 859

Paul Foulger, CFO

Mob: 07710 989 255

 

Panmure Gordon (UK) Limited

Tel: 020 7886 2500

Robert Naylor (Corporate Finance)

 

Paul Fincham (Corporate Finance)

 

 

 

Walbrook PR Limited 

Tel: 020 7933 8780 or ekf@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

   

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OUPEANEPFSKSFFF
Date   Source Headline
20th May 20265:41 pmRNSLong Term Incentive Plan Award
19th May 202612:24 pmRNSResult of AGM
19th May 20267:00 amRNSAGM statement & positive Q1 trading update
27th Apr 20267:00 amRNSBoard Changes
24th Apr 20264:43 pmRNSPosting of Annual Report & Notice of AGM
13th Apr 20267:00 amRNSAcquisition of assets from Beep Insights
10th Apr 20269:12 amRNSShare Buyback
8th Apr 20262:33 pmRNSShare Buyback
7th Apr 20261:09 pmRNSShare Buyback
2nd Apr 20267:00 amRNSShare Buyback
31st Mar 20265:59 pmRNSShare Buyback
24th Mar 20267:00 amRNSFull year results
20th Mar 202611:25 amRNSShare Buyback
19th Mar 202611:20 amRNSShare Buyback
19th Mar 20267:00 amRNSHolding(s) in Company
18th Mar 20269:58 amRNSShare Buyback
6th Mar 20267:00 amRNSShare Buyback
5th Mar 20267:00 amRNSNotice of Results
3rd Mar 20267:00 amRNSThree-year Hematology purchasing agreement
2nd Mar 20263:30 pmRNSTotal Voting Rights
27th Feb 20267:00 amRNSShare Buyback
19th Feb 20267:00 amRNSShare Buyback Programme
2nd Feb 20267:00 amRNSShare Buyback & Completion of Buyback Programme
30th Jan 20267:00 amRNSShare Buyback
29th Jan 20267:00 amRNSShare Buyback
28th Jan 202611:41 amRNSShare Buyback
27th Jan 20267:00 amRNSFY 2025 Trading Update
15th Jan 20267:00 amRNSShare Buyback
14th Jan 202611:43 amRNSShare Buyback
14th Jan 20269:37 amRNSShare Buyback
12th Jan 20269:45 amRNSShare Buyback
9th Jan 20265:00 pmRNSShare Buyback
8th Jan 20269:40 amRNSShare Buyback
6th Jan 20266:03 pmRNSShare Buyback
2nd Jan 202610:23 amRNSShare Buyback
31st Dec 202510:45 amRNSShare Buyback
31st Dec 202510:45 amRNSShare Buyback
30th Dec 20257:00 amRNSShare Buyback
30th Dec 20257:00 amRNSShare Buyback
29th Dec 20257:00 amRNSShare Buyback
29th Dec 20257:00 amRNSShare Buyback
24th Dec 202510:43 amRNSShare Buyback
24th Dec 202510:43 amRNSShare Buyback
23rd Dec 20255:23 pmRNSShare Buyback
23rd Dec 20255:23 pmRNSShare Buyback
22nd Dec 202511:10 amRNSShare Buyback
22nd Dec 202511:10 amRNSShare Buyback
16th Dec 20251:57 pmRNSShare Buyback
16th Dec 20257:00 amRNSExecutive Chair share purchase
8th Dec 20257:00 amRNSCancellation of Treasury Shares & TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.